key: cord-0315768-btvfke30
authors: Vidal, Jorge E.; Wier, Meagan N.; Angulo-Zamudio, Uriel; McDevitt, Erin; Jop Vidal, Ana G.; Alibayov, Babek; Scasny, Anna; Wong, Sandy M.; Akerley, Brian J.; McDaniel, Larry S.
title: Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite deoxycholic acid
date: 2021-05-18
journal: bioRxiv
DOI: 10.1101/2021.05.17.444594
sha: 3306dae079dcffb8195695a19ee755c330f2ee1a
doc_id: 315768
cord_uid: btvfke30

Streptococcus pneumoniae (Spn) colonizes the nasopharynx of children and the elderly but also kills millions worldwide yearly. The secondary bile acid metabolite, deoxycholic acid (DoC), affects the viability of human pathogens but also plays multiple roles in host physiology. We assessed in vitro the antimicrobial activity of DoC and investigated its potential to eradicate Spn colonization using an ex vivo model of human nasopharyngeal colonization and an in vivo mouse model of colonization. At a physiological concentration DoC (0.5 mg/ml; 1.27 mM) killed all tested Spn strains (N=48) two h post-inoculation. The ex-vivo model of nasopharyngeal colonization showed that DoC eradicated colonization by Spn strains as soon as 10 min post-exposure. The mechanism of action did not involve activation of autolysis since the autolysis-defective double mutants ΔlytAΔlytC and ΔspxBΔlctO were as susceptible to DoC as was the wild-type (WT). Oral streptococcal species (N=20), however, were not susceptible to DoC (0.5 mg/ml). Unlike trimethoprim, whose spontaneous resistance frequency (srF) for TIGR4 or EF3030 was ≥1×10−9, no spontaneous resistance was observed with DoC (srF≥1×10−12). Finally, the efficacy of DoC to eradicate Spn colonization was assessed in vivo using a topical route via intranasal (i.n.) administration and as a prophylactic treatment. Mice challenged with Spn EF3030 carried a median of 4.05×105 cfu/ml four days post-inoculation compared to 6.67×104 cfu/ml for mice treated with DoC. Mice in the prophylactic group had a ∼99% reduction of the pneumococcal density (median, 2.61 ×103 cfu/ml). Thus, DoC, an endogenous human bile salt, has therapeutic potential against Spn.

Introduction human pharyngeal cells. 141 To determine the exposure time required to kill pneumococci, we performed a time course 142 study treating MDR pneumococci colonizing human pharyngeal cells for up to one h with 0.5 mg/ml 143 (1.27 mM). Interestingly, a ten-minute exposure time was enough to kill most attached MDR 144 pneumococci (Fig. 2B) . The antimicrobial effect did not change with a longer exposure time of 60 145 min. These data indicate that 0.5 mg/ml (1.27 mM) of DoC rapidly eradicates MDR pneumococci 146 that otherwise would have colonized human nasopharyngeal cells at a density ∼10 7 cfu/ml (Fig. 2B ). 147 148 Spontaneous resistance to DoC (500 µg/ml) was not developed by S. pneumoniae strains. Spn 149 strains develop spontaneous resistance to some antibiotics at a spontaneous mutation frequency 150 >1x10 -8 (35). We assessed spontaneous resistance to DoC using antibiotic sensitive strains TIGR4 and 151 EF3030. As expected, spontaneous resistance against trimethoprim developed at a frequency of 152 ≥1.39x10 -9 when either pneumococcal strain was assessed (Fig. 3) . Spontaneous resistance to DoC, 153 however, was not observed in any of the two strains tested even at a population density >10 12 154 cfu/ml (Fig. 3) . 155 

The mechanism of DoC-killing does not appear to trigger autolysis. Since the above experiments 157 revealed that a short exposure time was sufficient to kill pneumococci, we hypothesized that an 158 irreversible autolytic mechanism may have been triggered by DoC. Autolysis is mainly driven by 159 autolysins LytA and LytC (36, 37) but hydrogen peroxide produced by the pneumococcus, through 160 enzymes SpxB and LctO, also contributes to lysis of pneumococci (38) (39) (40) . To assess this hypothesis, 161 we utilized strain R6 wt, its isogenic R6ΔlytAΔlytC mutant and a double R6ΔspxBΔlctO mutant to 162 assess the role of autolysis in the observed DoC-mediated bactericidal activity. Since autolysis can be 163 measured by quantifying the release of extracellular (e)DNA, we first confirmed that the absence of 164 the LytA and LytC autolysins, or SpxB and LctO, causes a decreased release of eDNA into the 165 supernatant. After four hours of incubation, the eDNA released by R6 wt strain reached a median of 166 2.24x10 6 pg/ml, whereas R6ΔspxBΔlctO released a statistically different two-fold decreased amount 167 of eDNA (median, 1.09x10 6 pg/ml) in the supernatant (Fig. 4A ). As expected, the autolysin double 168 mutant R6ΔlytAΔlytC yielded a ∼14-fold reduced amount of eDNA (median, 1.55x10 5 pg/ml) (Fig. 169 4A) compared to R6 wt. 170 These two mutant strains with an impaired autolysis phenotype were then challenged with we utilized Spn reference strain EF3030 (41, 42) . The median density of EF3030 untreated cultures 181 was 3.37x10 7 cfu/ml whereas those treated with 0.5 mg/ml DoC for 2 h had a median density of 182 3.1x10 2 cfu/ml, and therefore DoC killed 99.99% of the bacterial population (Fig. 5A) . However, the 183 same dose of DoC incubated for 2 h did not significantly affect the viability of S. oralis (Fig. 5B ), S. 184 mutans, (Fig. 5C ) S. gordonii, (Fig. 5D ) and induced a two-log reduction of the density of S. 185 anginosus. (Fig. 5E ). An additional 16 different streptococcal species were treated with DoC [0.5 186 mg/ml (1.27 mM)] for two hours and, except for S. pseudopneumoniae and S. salivarius that were 187 susceptible, cultures of all other species were not affected (Table 1) . 195 and pseudostratified, squamous epithelium overlaying by loose connective tissue including blood 196 vessels with erythrocytes (Fig. 6B ). Since our goal was to assess the efficacy of DoC to reduce, and/or 197 inhibits, nasopharyngeal colonization we investigated a low inoculum density of Spn EF3030 that 198 would sustain colonization of mice, but avoided using a non-natural (i.e., heavy) inoculum. Our 199 experiments demonstrated that inoculating ~1x10 5 cfu in the nostrils of mice allowed 200 nasopharyngeal colonization for up to four days at a median density of 2.49x10 5 cfu/organ (Fig. 6D ). 201 We additionally removed the trachea and lungs and demonstrated consistent Spn colonization of 202 the trachea, at a low density of 9.0x10 2 cfu/organ, but colonization of the lungs was not observed 203 ( Fig. 6D ). Encapsulated Spn were detected using an anti-S19-Alexa-555 antibody and were identified 204 both in nasopharyngeal homogenates (Fig. 6C ) and colonizing the nasopharyngeal tissue (Fig. 6E ). 205 Microinvasion into the nasopharyngeal epithelium was also observed (Fig. 6E ).

Deoxycholic acid (DoC) decreased in vivo colonization by S. pneumoniae strain EF3030 in a mouse 207 model of nasopharyngeal carriage. We then assessed the efficacy of DoC to eradicate colonization 208 using three groups of mice (N=8). Groups 1 and 2 drank regular water while the drinking water of 209 group 3 was supplemented with DoC at a concentration of 0.2 µg/ml (i.e., 0.02%) six days prior to 210 infection and remained in their drinking water throughout the experiment (Fig. 7A ). All three groups 211 were then challenged i.n. with Spn EF3030 (~1x10 5 cfu) and 24 h post-infection, mice in groups 1 and 212 2 were treated twice a day i.n. with 10 ul of a PBS solution or DoC (2 mg/ml), respectively. Mice 213 were euthanized 10 days after initiating the prophylactic regimen (i.e., oral administration) in 214 drinking water, or four days after placebo or DoC topical nasopharyngeal treatment began (Fig. 7A ). 215 Because of the oral and topical administration of DoC, we monitored the weight of mice daily 216 and no statistically significant difference in weight was observed between day one and the end of 217 the experiment in groups 1, 2, and 3 (Fig. 7B) . The colonization density of Spn was determined by x10 5 ; 75 th percentile, 5.94 x10 5 ). Although slightly reduced compared with the control group, this 222 colonization density was not statistically different. However, mice in the prophylactic DoC 223 administration group had a median Spn density of 2.61 x10 3 cfu/ml (25 th percentile, 1.5 x10 3 ; 75 th 224 percentile, 2.03 x10 4 ) and therefore, a significant reduction of nasopharyngeal colonization density 225 (e.g., 99.36% reduction) was achieved compared to the control group. We further extracted DNA 226 from those nasopharyngeal homogenates and the purified DNA was utilized as template in Spn-227 specific quantitative (q)PCR reactions. qPCR reactions confirmed a statistically significant decreased 228 density in the oral administration DoC-water group (median, 1.77x10 4 genome equivalents/ml) 229 compared with the control group (media, 6.70 x10 5 genome equivalents/ml) or with the topical DoC-230 nostril group (media, 1.15 x10 5 genome equivalents/ml) (Fig. 7D ). Reports describing Spn strains that were not soluble in DoC using the subjective visual 283 readout are available; however, neither the semiquantitative assay nor our viability screening 284 identified strains reduced in or lacking susceptibility to DoC (60). The possibility remains that some 285 pneumococcal strains isolated from pneumococcal disease cases, or those colonizing healthy 286 individuals, are naturally resistant to DoC. Spontaneous resistance to DoC when assessed using 287 strains TIGR4 and EF3030 was not achieved even at bacterial populations >10 12 cfu/ml. The same 288 strains, when challenged with trimethoprim, generated spontaneous resistant bacteria at a 289 frequency of ≥1.39x10 -9 A similar spontaneous resistance frequency to trimethoprim (35), to that 290 found in the current study, or spontaneous mutation to optochin (61) Table 1 atmosphere after which the cultures were serially diluted and plated onto blood agar plates to 444 obtain the density (cfu/ml). Error bars represent the standard errors of the means calculated using 445 data from at least three independent experiments. The limit of detection (LOD) was <10 cfu/ml. with 3% lysed horse blood. S. pneumoniae strain TIGR4 was inoculated at a density of ∼5.15x10 8 cfu/ml into CAMHB-LHB and left untreated (control) or treated with 0.5, 1, or 2 mg/ml of 519 deoxycholic acid (DoC). Bacteria were incubated ∼20 h at 37°C in a 5% CO 2 atmosphere after which 520 the cultures were serially diluted and plated onto blood agar plates to obtain the density (cfu/ml). 521 Error bars represent the standard errors of the means calculated using data from at least three 522 independent experiments. The median density is shown inside the control bar or above DoC (0.5). 523 Limit of detection (LOD) was <10 cfu/ml. 

Impact of pneumococcal conjugate 583 vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: 584 review of evidence on indirect effects

Efficacy of pneumococcal conjugate vaccines and their effect on carriage 586 and antimicrobial resistance

The potential indirect effect of conjugate pneumococcal vaccines

Effect of 13-590 valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its 591 introduction in the USA: a time series analysis

Serotype-specific changes in invasive pneumococcal disease 594 after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple 595 surveillance sites

Invasive pneumococcal disease caused by nonvaccine serotypes among 598 alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

Serotype replacement in disease after 601 pneumococcal vaccination

The Intestinal Microbiome Restricts Alphavirus 605 Infection and Dissemination through a Bile Acid-Type I IFN Signaling Axis

Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice

Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during 631

Clostridioides difficile Infection by Altering Gut Bile Acids

Inhibiting Growth of Clostridioides difficile by Restoring 634

Produced by the Intestinal Microbiota

In vitro synergy of 5-nitrofurans, 636 vancomycin and sodium deoxycholate against Gram-negative pathogens

Bile Acid 7alpha-Dehydroxylating Gut Bacteria Secrete 640

e4. 642 34. Institute. CaLS. 2020. Performance Standards for Antimicrobial Susceptibility Testing

Thirtieth Informational Supplement. M100-S30

Effect of subinhibitory concentrations of 645 antibiotics on mutation frequency in Streptococcus pneumoniae

Streptococcus pneumoniae: contributions and role of the cell wall hydrolases CbpD

New insights into the 651 pneumococcal fratricide: relationship to clumping and identification of a novel immunity 652 factor

Radicals That Rapidly 656 Immunization with Pneumococcal Surface Protein K of Nonencapsulated Streptococcus 674 pneumoniae Provides Protection in a Mouse Model of Colonization

Practice Guideline of the

BTS guidelines for the management of community acquired pneumonia in 684 adults: update

Postprandial concentrations of free and conjugated bile acids 686 down the length of the normal human small intestine

Determination of intralumenal individual bile 688 acids by HPLC with charged aerosol detection

Antibiotic 691 treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated 692 transmission, and severe disease in immunocompromised hosts

The immunomodulatory role of bile acids

Bile acids in regulation of intestinal physiology

Bile 698 acids deoxycholic acid and ursodeoxycholic acid differentially regulate human beta-defensin-699 1 and -2 secretion by colonic epithelial cells

Quantification of bile acids: a mass spectrometry platform for 702 studying gut microbe connection to metabolic diseases

Bile Acids Quantification by Liquid Chromatography-Tandem Mass 705

Spectrometry: Method Validation, Reference Range, and Interference Study

The bile acids, deoxycholic acid and 708 ursodeoxycholic acid, regulate colonic epithelial wound healing

The Agglutination of the Pneumococcus with certain Normal and 711

Identification of Streptococcus pneumoniae and other Mitis 713 streptococci: importance of molecular methods

Standard method for detecting upper respiratory carriage of Streptococcus 717 29 pneumoniae: updated recommendations from the World Health Organization Pneumococcal 718

Assessment of a novel bile solubility test and 720

MALDI-TOF for the differentiation of Streptococcus pneumoniae from other mitis group 721 streptococci

Ambiguity in the 723 identification of Streptococcus pneumoniae. Optochin, bile solubility, quellung

AccuProbe DNA probe tests

Characterization of in vitro-726 generated and clinical optochin-resistant strains of Streptococcus pneumoniae isolated from 727

Microinvasion by Streptococcus 730 pneumoniae induces epithelial innate immunity during colonisation at the human mucosal 731 surface

Choline-containing teichoic acid as a structural component of 733 pneumococcal cell wall and its role in sensitivity to lysis by an autolytic enzyme

Evaluation of a medium (STGG) for transport 737 and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions 738 collected during field studies

The LuxS-dependent 740 quorum-sensing system regulates early biofilm formation by Streptococcus pneumoniae 741 strain D39

Competitive Dominance within Biofilm Consortia Regulates the 744

Relative Distribution of Pneumococcal Nasopharyngeal Density

Pneumococcal interactions with epithelial 746 cells are crucial for optimal biofilm formation and colonization in vitro and in vivo

Quorum-sensing systems 30

Single-762 plex quantitative assays for the detection and quantification of most pneumococcal 763 serotypes

Complete genome sequence of a virulent isolate of Streptococcus pneumoniae

Genome sequence of Avery's virulent serotype 2 strain D39 of 773

Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain 774 R6

Hydrogen Peroxide Production by Streptococcus pneumoniae Results in Alpha-hemolysis by 777 Oxidation of Oxy-hemoglobin to Met-hemoglobin. mSphere 5

Biofilm formation by Streptococcus pneumoniae: role 779 of choline, extracellular DNA, and capsular polysaccharide in microbial accretion

Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci 783 attaching to human pharyngeal epithelial cells

High-Level Macrolide Resistance 785

Due to the Mega Element [mef(E)/mel] in Streptococcus pneumoniae